Key facts
- It has raised $12.6M.
- Notable investors include Innovate UK, BGF (Financial Services), Parkwalk Advisors, Cambridge Angels, Cambridge Enterprise Ventures — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Abselion
- ·The full record, as it builds
Funding rounds
No funding rounds for Abselion are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Abselion
Developer of biosensor technologies designed to simplify the analysis of proteins and small molecules for pharma research and manufacturing. The company's diagnostic analyzers and kits help to analyze biomolecular interactions like protein interaction analysis, enabling researchers to obtain sensitive, rapid, and near-real-time medical diagnoses.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2017
- Employees
- 24
- Website
- abselion.com/
- Ownership
- Privately Held (backing)
Abselion doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Abselion shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Abselion in its N-PORT filings yet. We sweep new filings monthly.